Cargando…
C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer
BACKGROUND: At present, node-negative, high-risk breast cancer patients cannot be identified with sufficient accuracy. Consequently, further strong prognostic factors are needed. METHODS: Among 181 node-negative breast cancer (NNBC) patients, c-myc and HER-2/neu oncogenes were identified prospective...
Autores principales: | Schlotter, Claus M, Vogt, Ulf, Bosse, Ulrich, Mersch, Berthold, Waβmann, Katja |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC154146/ https://www.ncbi.nlm.nih.gov/pubmed/12631396 |
Ejemplares similares
-
Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing
por: Schmidt, Marcus, et al.
Publicado: (2005) -
Factors Influencing Lymph Node Positivity in HER2/neu+ Breast Cancer Patients
por: Englander, Katherine, et al.
Publicado: (2023) -
Breast Cancer and Her-2/Neu
por: Sherwood, Roy
Publicado: (2005) -
Detection of HER-2/neu, c-myc amplification and p53 inactivation by FISH in Egyptian patients with breast cancer
por: Ismail, Manal F., et al.
Publicado: (2009) -
HER2/neu negative salivary duct carcinoma of parotid: A case with forty months recurrence free follow up
por: Gokavarapu, Sandhya, et al.
Publicado: (2015)